Jacob Sands, MD / Raffaele Califano, MD - Novel ADC Targets in Advanced NSCLC: Examining Emerging Strategies for TROP2-Directed ADCs

episode

CME in Minutes: Education in Primary Care not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Booked out doesn't mean you're ready for an associate OD 23 min · 23 Sep 2026 · The Optometry Success Podcast

Alt.Latino: YEИDRY's life in six songs 38 min · 23 Sep 2026 · NPR Music

Neil Young 1h 33m · 23 Sep 2026 · Tetragrammaton with Rick Rubin

Warnings (PODCAST EXCLUSIVE EPISODE) 27 min · 23 Sep 2026 · MrBallen Podcast: Strange, Dark & Mysterious Stories

Larry the Cable Guy on His Origin Story, Blue-Collar Comedy & Buckin’ Bulls! 1h 47m · 23 Sep 2026 · Adam Carolla Show

Gaining an edge in Financial Markets with Mike Bell, CFA - Part 2 37 min · 23 Sep 2026 · The MOST Important Thing

Report any issue

Source

Recorded30 Oct 2024

Publisherc.answersincme.com ↗

Handlerec:10296273

Show notes

Please visit answersincme.com/93496951-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in NSCLC discuss the significance of the latest data for TROP2-directed ADCs in NSCLC. Upon completion of this activity, participants should be better able to: Explain the rationale for antibody drug conjugates (ADCs) in the treatment of advanced non-small cell lung cancer (NSCLC); Identify the latest efficacy and safety data for ADCs in advanced NSCLC; and Recognize key clinical factors to optimize the evidence-based use of current and emerging ADCs in advanced NSCLC.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in